ArticleClinical epidemiology2021
Epidemiology of Vitiligo - A Dual Population-Based Approach.
Article in Clinical epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Vitiligo and the microbiome of the gut and skin: a systematic review.Archives of dermatological research · 2025Pooled it
- [Vitiligo in Germany : A claims data analysis on prevalence, comorbidity, and treatment patterns].Dermatologie (Heidelberg, Germany) · 2026Article
- [Medical care situation of people with vitiligo : A pilot and feasibility study on guideline-oriented management in German dermatology practices].Dermatologie (Heidelberg, Germany) · 2026Observational
- Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.Dermatology and therapy · 2026Article
- Epidemiology and Comorbidity of Vitiligo in Germany: A Claims Data Analysis.Acta dermato-venereologica · 2026Article
- Vitiligo.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- [Vitiligo-update on pathogenesis, diagnostics and therapy].Dermatologie (Heidelberg, Germany) · 2025Review
- Estimation of genetic variation in vitiligo associated genes: Population genomics perspective.BMC genomic data · 2024Article
- [Quality of life, disease burden and healthcare need of patients with vitiligo].Dermatologie (Heidelberg, Germany) · 2024Review
- Review
- Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Article
- Audiological and vestibular evaluations in vitiligo patients.Bosnian journal of basic medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost epidemiological data on vitiligo refer to selected environments or focus on the prevalence of comorbidity unrelated to the population.
objectiveAim of the study was to gain robust representative prevalence data on vitiligo and on associated dermatologic comorbidity in the German adult population.
methodsA dual population-based approach was applied with 1) primary data obtained between 2004 and 2014 from dermatological exams in the general working population; 2) claims data from a large German statutory health insurance, reference year 2010.
resultsIn the working cohort (N = 121,783; 57% male; mean age 43 years), the prevalence of vitiligo was 0.77% (0.84% in men; 0.67% in women). In the claims data (N = 1,619,678; 38% male; mean age 46 years), prevalence was 0.17% (0.14% in men; 0.18% in women). In the working cohort, vitiligo was significantly more common in people with fair skin type, ephelides and port-wine stains and less common in people with acne and solar lentigines. In the claims data, vitiligo was associated with a variety of skin conditions, eg, atopic dermatitis, psoriasis and alopecia areata.
conclusionThe resulting discrepancy of claims vs primary data between 0.17% and 0.77% indicates the most probable spectrum of vitiligo prevalence in Germany. It is more frequently observed in clinical exams than recorded in claims data, indicating a marked proportion of people seeking no medical help. Such nonattendance may result from the fact that many treatment options do not provide satisfying benefits to the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.